(Reuters) - Russia's granting of regulatory approval to a COVID-19 vaccine after less than two months of human testing has prompted expressions of caution as well as interest from around the world.
Moscow said on Wednesday that the first batch of the vaccine would be ready for some medics within two weeks and rejected safety concerns as "groundless".
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!